Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThruvision Grp Regulatory News (THRU)

Share Price Information for Thruvision Grp (THRU)

Share Price is delayed by 15 minutes
Get Live Data
0.725    0.00 (0.00%)
Bid:
0.70
Ask:
0.75
Spread: 0.05 (7.143%)
Market Cap: £3.24m
THRU Live PriceLast checked at - London Stock Exchange

Intraday Thruvision Grp Share Chart

New product launch

26 Feb 2025 15:16

RNS Number : 5858Y
Thruvision Group PLC
26 February 2025
 

26 February 2025

Thruvision Group plc

Thruvision Launches Next Generation AI Powered 81 Series Passive People Screening Systems

 

Thruvision (AIM: THRU, "Thruvision" or the "Group"), the leading international provider of walk- through security technology, today launches its latest series of products.

 

Thruvision is proud to introduce the 81 Series, the next generation of our world-leading people security screening technology. Designed for use in all markets, the new 81 Series represents the latest evolution in Thruvision's proven people screening technology.

 

The 81 Series features an all-new modular design with integrated touchscreen control, offering a compact, mobile, and unobtrusive solution. This cutting-edge design provides exceptional ergonomics for quick and easy deployment in a wide range of screening operations.

 

Building upon our core principles of treating subjects with respect and privacy, the 81 Series allows for the instant visualisation of threats without the need for pat-downs. Our latest space-grade technology ensures reliability and support for mission-critical operations.

 

The mobile systems enable detection-at-range with a new optional integrated battery pack, providing ultimate flexibility. Capable of screening up to 1,800 people per hour with our WalkTHRU concept of operations, the 81 Series is designed to meet the demands of high-throughput environments.

 

The system detects all materials using our latest and exclusive SmartSCREEN and DynamicDETECT AI software. Available in four models, the 81 Series supports all operation types, from border and entrance security to loss prevention.

 

We invite you to experience the future of people security screening with the Thruvision 81 Series.

 

Further InformationFor more information please visit thruvision.com or email info@thruvision.com

 

81 Series Media Assets

https://drive.google.com/drive/folders/10ybKnqQv_-o0U4dmrRRmUOKsVAGT4zdN?usp=sharing

 

About Thruvision (www.thruvision.com)

Thruvision is the leading developer, manufacturer and supplier of advanced AI-based walk- through security technology internationally. Its technology is deployed in more than 30 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using advanced AI-based detection algorithms. The Group's offices are near Oxford and Washington DC.

 

Important information

This announcement may include statements that are, or may be deemed to be, 'forward-looking statements' (including words such as 'believe', 'expect', 'estimate', 'intend', 'anticipate' and words of similar meaning). By their nature, forward-looking statements involve risk and uncertainty since they relate to future events and circumstances, and actual results may, and often do, differ materially from any forward-looking statements. Any forward-looking statements in this announcement reflect management's view with respect to future events as at the date of this announcement. Save as required by applicable law, the Company undertakes no obligation to publicly revise any forward-looking statements in this announcement, whether following any change in its expectations or to reflect events or circumstances after the date of this announcement.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUCGPUPAGAQ
Date   Source Headline
31st May 20245:06 pmRNSHolding(s) in Company
30th May 20247:00 amRNSThruvision partners with Sensormatic Solutions
22nd May 202412:26 pmRNSBlock listing Interim Review
22nd May 202412:26 pmRNSBlock listing Interim Review
26th Apr 20247:00 amRNSYear-end trading update
18th Mar 20247:00 amRNSWalkTHRU completes operational test and evaluation
1st Feb 20247:00 amRNSNext generation product range & software launched
26th Jan 20247:00 amRNSSales Progress Update
22nd Jan 20242:48 pmRNSHolding(s) in Company
10th Jan 202410:39 amRNSAward of Share Options to Executive Director
28th Nov 202311:50 amRNSBlocklisting update
28th Nov 202311:48 amRNSBlocklisting update
20th Nov 20237:00 amRNSInterim Results
13th Nov 20238:51 amRNSUK retail theft to cost £7.9bn in 2023
6th Nov 20234:27 pmRNSNotice of Interim Results
27th Oct 202311:32 amRNSHolding(s) in Company
26th Oct 20232:34 pmRNSHolding(s) in Company
26th Oct 20232:23 pmRNSHolding(s) in Company
25th Oct 202312:04 pmRNSHolding(s) in Company
24th Oct 20237:00 amRNSResult of placing
23rd Oct 20234:35 pmRNSLaunch of placing
2nd Oct 20237:00 amRNSHalf year trading update
21st Sep 202311:12 amRNSResult of Annual General Meeting
22nd Aug 202311:56 amRNSAward of Share Options to Executive Directors
21st Jul 20237:00 amRNSResults for the year ended 31 March 2023
13th Jul 20235:09 pmRNSNotice of Results
7th Jun 20237:00 amRNSBlocklisting update
7th Jun 20237:00 amRNSBlocklisting update
21st Apr 20237:00 amRNSYear end trading update
3rd Feb 20237:00 amRNSSharesave option grant to Executive Director
12th Jan 202310:24 amRNSChange of Auditor
21st Dec 20227:00 amRNSDirector Share Dealing
19th Dec 20227:00 amRNSInterim Results
15th Dec 20227:00 amRNSCORRECTION - Blocklisting Update
13th Dec 20227:00 amRNSBlocklisting Update
13th Dec 20227:00 amRNSBlocklisting Update
30th Nov 20227:00 amRNSNotice of Results
9th Nov 20227:00 amRNSAward of Share Options to Executive Directors
8th Nov 20222:50 pmRNSHolding(s) in Company
26th Oct 202211:50 amRNSResult of AGM
12th Oct 20227:00 amRNSH1 Trading Update
3rd Oct 20227:00 amRNSCBP Framework Agreement and Contract Award
30th Sep 20227:00 amRNSResults for the Year ended 31 March 2022
22nd Sep 20223:00 pmRNSContract Award, Trading Update, Notice of Results
16th Jun 20227:00 amRNSAppointment of Chief Financial Officer
15th Jun 20228:31 amRNSHolding(s) in Company
8th Jun 20223:32 pmRNSBlocklisting update
8th Jun 20223:30 pmRNSBlocklisting update
6th May 202212:12 pmRNSDirector Share Dealing-correction & further trade
20th Apr 20227:00 amRNSDirector Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.